{"links": [{"source": 0, "target": "t915", "value": "None"}, {"source": 0, "target": "t913", "value": "None"}, {"source": 0, "target": "t907", "value": "None"}, {"source": "t915", "target": "t918", "value": "None"}, {"source": "t915", "target": "t916", "value": "None"}, {"source": "t915", "target": "t925", "value": "None"}, {"source": "t915", "target": "t924", "value": "None"}, {"source": "t915", "target": "t926", "value": "None"}, {"source": "t915", "target": "t917", "value": "None"}, {"source": "t907", "target": "t914", "value": "None"}, {"source": "t907", "target": "t908", "value": "None"}, {"source": "t907", "target": "t910", "value": "None"}, {"source": "t918", "target": "t919", "value": "None"}, {"source": "t916", "target": "t918", "value": "None"}, {"source": "t925", "target": "d201", "value": "None"}, {"source": "t917", "target": "t918", "value": "None"}, {"source": "t908", "target": "t909", "value": "None"}, {"source": "t910", "target": "t912", "value": "None"}, {"source": "t910", "target": "t911", "value": "None"}, {"source": "t919", "target": "t920", "value": "None"}, {"source": "t920", "target": "t921", "value": "None"}, {"source": "t921", "target": "t923", "value": "None"}, {"source": "t921", "target": "t922", "value": "None"}], "nodes": [{"category": "disease", "id": 0, "name": "Metastases", "x": "250", "y": "350", "fixed": "true", "draggable": "true", "value": {"name": "Metastases"}}, {"category": "treatment", "id": "t915", "name": "adult with spinal pain and/or at risk of spinal metastases", "draggable": "true", "value": {"name": "adult with spinal pain and/or at risk of spinal metastases", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:adult with spinal pain and/or at risk of spinal metastases", "drug": {}}}, {"category": "treatment", "id": "t913", "name": "the role of the carcinoma of unknown primary origin (cup) team", "draggable": "true", "value": {"name": "the role of the carcinoma of unknown primary origin (cup) team", "type": "information and support", "time": "", "intention": "", "description": "title:the role of the carcinoma of unknown primary origin (cup) teamhead:The role of the carcinoma of unknown primary origin (CUP) teamThe CUP team should: include an oncologist, a palliative care physician and a CUP specialist nurse or key worker (see below) as a minimum have administrative support have sufficient designated time in their job plans for their role have a named lead clinician (see below) after referral, assess MUO inpatients by the end of the next working day and outpatients within 2 weeks write a management plan for each patient including investigations, symptom control, access to psychological support and information actively review the outcome of all investigations with a nominated pathologist and radiologist as appropriate be involved in the patient s care until they are: referred to a site-specialist consultant or referred for palliative care alone or diagnosed with a non-malignant condition continue managing the patient s care if confirmed CUP is diagnosed.subhead:Role of the CUP specialist nurse or key workerThe CUP specialist nurse or key worker should: take a major role in coordinating the patient s care in line with this guidance liaise with the patient s GP and other community support services ensure that patients and carers can get information, advice and support about diagnosis, treatment, palliative care and spiritual and psychosocial concerns meet the patient soon after referral and keep in close contact regularly by mutual agreementbe an advocate for the patient at CUP team meetings.subhead:Role of the named lead clinicianThe named lead clinician should: take managerial responsibility for the CUP service in the cancer centre or unit ensure there is a clinical system for the appropriate care of MUO and CUP patients ensure each patient has an identified CUP specialist nurse or key worker (see above) ensure there is cover for all members of the CUP team during absence ensure senior clinical input is available to inform decision-making and treat patients ensure there is a single point of contact for the patient to access the CUP team implement the care pathway and help educate other healthcare professionals in diagnosing and managing MUO and CUP ensure timely and effective communication between healthcare professionals caring for patients with MUO or CUP, including primary and palliative care represent the cancer centre or unit at the CUP network site-specific group and CUP network MDTLocal arrangements for accessing a specialist CUP MDT may vary. contribute to regular local and network audits of the management of MUO or CUP.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG104", "drug": {}}}, {"category": "treatment", "id": "t907", "name": "patient with malignancy of undefined primary origin", "draggable": "true", "value": {"name": "patient with malignancy of undefined primary origin", "type": "information and support", "time": "", "intention": "", "description": "title:patient with malignancy of undefined primary origin", "drug": {}}}, {"category": "treatment", "id": "t918", "name": "suspected spinal metastases and metastatic spinal cord compression", "draggable": "true", "value": {"name": "suspected spinal metastases and metastatic spinal cord compression", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:suspected spinal metastases and metastatic spinal cord compressionhead:Suspected spinal metastases and metastatic spinal cord compressionContact the MSCC coordinator urgently (within 24 hours) to discuss the care of patients with cancer and any of the following symptoms suggestive of spinal metastases: pain in the middle (thoracic) or upper (cervical) spine progressive lower (lumbar) spinal pain severe unremitting lower spinal pain spinal pain aggravated by straining (for example, at stool, or when coughing or sneezing) localised spinal tenderness nocturnal spinal pain preventing sleep.Contact the MSCC coordinator immediately to discuss the care of patients with cancer and symptoms suggestive of spinal metastases who have any of the following neurological symptoms or signs suggestive of MSCC, and view them as an oncological emergency: neurological symptoms including radicular pain, any limb weakness, difficulty in walking, sensory loss or bladder or bowel dysfunction neurological signs of spinal cord or cauda equina compression.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG75", "drug": {}}}, {"category": "treatment", "id": "t916", "name": "non specific lower spinal pain in adult with cancer", "draggable": "true", "value": {"name": "non specific lower spinal pain in adult with cancer", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:non-specific lower spinal pain in adult with cancerhead:Non-specific lower spinal pain in adult with cancerPerform frequent clinical reviews of patients with cancer who develop lower spinal pain that is clinically thought to be of non-specific origin (that is, it is not progressive, severe or aggravated by straining and has no accompanying neurological symptoms). In particular, look for: development of progressive pain or other symptoms suggestive of spinal metastases (contact the MSCC coordinator within 24 hours), or development of neurological symptoms or signs suggestive of MSCC (contact the MSCC coordinator immediately).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG75", "drug": {}}}, {"category": "treatment", "id": "t925", "name": "service organisation", "draggable": "true", "value": {"name": "service organisation", "type": "cancer ralated", "time": "", "intention": "daytime\ndaytime is a combination medicine used to treat headache, fever, body aches, cough, stuffy nose, and sinus congestion caused by allergies, the common cold, or the flu.\ndaytime may also be used for purposes not listed in this medication guide.", "description": "title:service organisationhead:Service organisationsubhead:Cancer networkEvery cancer network should have a clear care pathway for the diagnosis, treatment, rehabilitation and ongoing care of patients with MSCC.Every cancer network should ensure that appropriate services are commissioned and in place for the efficient and effective diagnosis, treatment, rehabilitation and ongoing care of patients with MSCC. These services should be monitored regularly through prospective audit of the care pathway.Cancer networks should ensure that there is local access to urgent MRI within 24 hours for all patients with suspected MSCC. This service should be available outside normal working hours and with 24-hour capability in centres treating patients with MSCC.Every cancer network should have a network site specific group for MSCC. The group should include representatives from primary, secondary and tertiary care and should have strong links to network site specific groups for primary tumours.The cancer network should appoint a network lead for MSCC whose responsibilities include: advising the cancer network, commissioners and providers about the provision and organisation of relevant clinical services ensuring that the local care pathway for diagnosis and management are documented, agreed and consistent across the network ensuring that there are appropriate points of telephone contact for the role of an MSCC coordinator and senior clinical advisers maintaining a network-wide audit of the incidence, timeliness of management, and outcomes of patients with MSCC using nationally agreed measures arranging and chairing twice-yearly meetings of the network site specific group for MSCC, at which patient outcomes will be reported and the local care pathway reviewed and amended if necessary.subhead:Secondary or tertiary care centreEvery secondary or tertiary care centre should have an identified lead healthcare professional for MSCC (who is usually, but not necessarily, medical) whose responsibilities include: representing the hospital at network level in the development of care pathways implementing the care pathway and disseminating information about the diagnosis and appropriate management of patients with known or suspected MSCC ensuring timely and effective communication between all relevant healthcare professionals involved in the care of patients with MSCC, including primary care and palliative care raising and maintaining the awareness and understanding of treatments for MSCC among all clinical staff across the locality contributing to regular network audits of the care of patients with MSCC attending and contributing to the twice-yearly network site specific group meeting.Commissioners should establish a joint approach with councils responsible for local social services to ensure efficient provision of equipment and support, including nursing and rehabilitation services, to meet the individual needs of patients with MSCC and their families and carers.Each centre treating patients with MSCC should identify or appoint individuals responsible for performing the role of MSCC coordinator and ensure its availability at all times.Each centre treating patients with MSCC should have a single point of contact to access the MSCC coordinator who should provide advice to clinicians and coordinate the care pathway at all times.The MSCC coordinator should: provide the first point of contact for clinicians who suspect that a patient may be developing spinal metastases or MSCC perform an initial telephone triage by assessing requirement for, and urgency of, investigations, transfer, and treatment advise on the immediate care of the spinal cord and spine and seek senior clinical advice, as necessary gather baseline information to aid decision-making and collate data for audit purposes identify the appropriate place for timely investigations and admission if required liaise with the acute receiving team and organise admission and mode of transport.The optimal care of patients with MSCC should be determined by senior clinical advisers (these include clinical oncologists, spinal surgeons and radiologists with experience and expertise in treating patients with MSCC), taking into account the patient s preferences and all aspects of their condition, with advice from primary tumour site clinicians or other experts, as required.Every centre treating patients with MSCC should ensure 24-hour availability of senior clinical advisers to give advice and support to the MSCC coordinator and other clinicians, inform the decision-making process and undertake treatment where necessary.Imaging departments should configure MRI lists to permit time for examination of patients with suspected MSCC at short notice during existing or extended sessions (by moving routine cases into ad hoc overtime or to alternative sessions, if overtime is not possible).Ensure urgent (within 24 hours) access to and availability of radiotherapy and simulator facilities in daytime sessions, 7 days a week for patients with MSCC requiring definitive treatment or who are unsuitable for surgery.NICE has published cancer service guidance on improving supportive and palliative care for adults with cancer.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.4Coordinating investigations for adults with suspected metastatic spinal cord compression5Coordinating care for adults with metastatic spinal cord compressionSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG75", "drug": {}}}, {"category": "treatment", "id": "t924", "name": "asymptomatic patient with cancer", "draggable": "true", "value": {"name": "asymptomatic patient with cancer", "type": "treatment related", "time": "", "intention": "", "description": "title:asymptomatic patient with cancerhead:Asymptomatic patient with cancerIn patients with a previous diagnosis of malignancy, routine imaging of the spine is not recommended if they are asymptomatic.Serial imaging of the spine in asymptomatic patients with cancer who are at high risk of developing spinal metastases should only be performed as part of a randomised controlled trial.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG75", "drug": {}}}, {"category": "treatment", "id": "t926", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t917", "name": "suspicious spinal pain in adult without diagnosis of cancer", "draggable": "true", "value": {"name": "suspicious spinal pain in adult without diagnosis of cancer", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:suspicious spinal pain in adult without diagnosis of cancerhead:Suspicious spinal pain in adult without diagnosis of cancerPerform frequent clinical reviews of patients without a prior diagnosis of cancer who develop suspicious spinal pain with or without neurological symptoms. Treat or refer patients with stable and mild symptoms by normal non-specific spinal pathways, or refer by cancer pathway if concerned. In particular, look for: development of progressive pain or other symptoms suggestive of spinal metastases (contact the MSCC coordinator within 24 hours), or development of neurological symptoms or signs suggestive of MSCC (contact the MSCC coordinator immediately).See what NICE says on suspected cancer recognition and referral and metastatic malignant disease of unknown primary origin.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG75", "drug": {}}}, {"category": "treatment", "id": "t914", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t908", "name": "investigation and diagnosis", "draggable": "true", "value": {"name": "investigation and diagnosis", "type": "treatment related", "time": "", "intention": "", "description": "title:investigation and diagnosis", "drug": {}}}, {"category": "treatment", "id": "t910", "name": "service organisation", "draggable": "true", "value": {"name": "service organisation", "type": "cancer ralated", "time": "", "intention": "", "description": "title:service organisationhead:Service organisationNICE has published a cancer service guideline on improving supportive and palliative care for adults with cancer.", "drug": {}}}, {"category": "treatment", "id": "t919", "name": "information and support", "draggable": "true", "value": {"name": "information and support", "type": "information and support", "time": "", "intention": "", "description": "title:information and supporthead:Information and supportEnsure that communication with patients with known or suspected MSCC is clear and consistent, and that the patients, their families and carers are fully informed and involved in all decisions about treatment.Offer patients with MSCC and their families and carers specialist psychological and/or spiritual support appropriate to their needs at diagnosis, at other key points during treatment and on discharge from hospital.Provide information to patients with MSCC in an appropriate language and format that explains how to access psychological and/or spiritual support services when needed.Inform patients at high risk of developing bone metastases, patients with diagnosed bone metastases, or patients with cancer who present with spinal pain about the symptoms of MSCC. Offer information (for example, in the form of a leaflet) to patients and their families and carers which explains the symptoms of MSCC, and advises them (and their healthcare professionals) what to do if they develop these symptoms.Ensure that patients with MSCC and their families and carers know who to contact if their symptoms progress while they are waiting for urgent investigation of suspected MSCC.Offer bereavement support services to patients  families based on the three component model outlined in improving supportive and palliative care for adults with cancer.NICE has written information for the public on metastatic spinal cord compression. Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.1Information about recognising the symptoms of metastatic spinal cord compressionSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG75", "drug": {}}}, {"category": "treatment", "id": "t909", "name": "management", "draggable": "true", "value": {"name": "management", "type": "treatment related", "time": "", "intention": "", "description": "title:management", "drug": {}}}, {"category": "treatment", "id": "t912", "name": "local level", "draggable": "true", "value": {"name": "local level", "type": "information and support", "time": "", "intention": "", "description": "title:local levelhead:Local levelEvery hospital cancer centre or unit should: set up a CUP team ensure patients have access to the CUP team when MUO is diagnosed assign a specialist nurse or key worker to patients with MUO or CUP  upgrade patients to the cancer waiting times pathway when MUO is suspected or first diagnosed ensure services are set up for rapid and appropriate investigation in line with this guidance ensure staff are appropriately trained.For more information about the CUP team, see the role of the carcinoma of unknown primary origin (CUP) team.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG104", "drug": {}}}, {"category": "treatment", "id": "t911", "name": "national and regional level", "draggable": "true", "value": {"name": "national and regional level", "type": "information and support", "time": "", "intention": "", "description": "title:national and regional levelhead:National and regional levelCUP network MDTsLocal arrangements for accessing a specialist CUP MDT may vary. should be set up to: review the treatment and care of patients with confirmed CUP, or those with MUO or provisional CUP and complex diagnostic or treatment issues carry out established specialist MDT responsibilities.Every cancer network should set up a network site-specific group to define and oversee policies for managing CUP. The group should: ensure that CUP teams are properly set up (for more information about the CUP team, see the role of the carcinoma of unknown primary origin (CUP) team)  ensure the local care pathway for CUP is in line with this guidance be aware of the variety of routes by which newly diagnosed patients present advise the cancer network on CUP-related matters, recognising that there is often limited experience of CUP maintain a network-wide audit of the incidence and timely management of CUP and patient outcomes arrange regular group meetings to report patient outcomes and review the local care pathway.For MUO and CUP: data and coding definitions should be developed and used in routine statistics a minimum data set should be agreed nationally, collected by clinicians and reviewed at network level a national audit should be set up based on the agreed minimum data set the National Cancer Intelligence Network should analyse current epidemiology data and the use of the NHS by MUO and CUP patients.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG104", "drug": {}}}, {"category": "treatment", "id": "t920", "name": "initial management of suspected metastatic spinal cord compression", "draggable": "true", "value": {"name": "initial management of suspected metastatic spinal cord compression", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:initial management of suspected metastatic spinal cord compressionhead:Initial management of suspected metastatic spinal cord compressionPatients with severe mechanical pain suggestive of spinal instability, or any neurological symptoms or signs suggestive of MSCC, should be nursed flat with neutral spine alignment (including  log rolling  or turning beds, with use of a slipper pan for toilet) until bony and neurological stability are ensured and cautious remobilisation may begin.Offer all patients who are on bed rest with suspected MSCC thigh-length graduated compression/anti-embolism stockings unless contraindicated, and/or intermittent pneumatic compression or foot impulse devices.Patients with suspected MSCC, a poor performance status and widespread metastatic disease should wherever possible be discussed with their primary tumour site clinician and spinal senior clinical adviser before any urgent imaging or hospital transfer.Patients with suspected MSCC who have been completely paraplegic or tetraplegic for more than 24 hours should wherever possible be discussed urgently with their primary tumour site clinician and spinal senior clinical adviser before any imaging or hospital transfer.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG75", "drug": {}}}, {"category": "treatment", "id": "t921", "name": "imaging", "draggable": "true", "value": {"name": "imaging", "type": "treatment related", "time": "", "intention": "", "description": "title:imaginghead:ImagingPerform MRI of the whole spine in patients with suspected MSCC, unless there is a specific contraindication. This should be done in time to allow definitive treatment to be planned within 1 week of the suspected diagnosis in the case of spinal pain suggestive of spinal metastases, and within 24 hours in the case of spinal pain suggestive of spinal metastases and neurological symptoms or signs suggestive of MSCC, and occasionally sooner if there is a pressing clinical need for emergency surgery.MRI of the spine in patients with suspected MSCC should be supervised and reported by a radiologist and should include sagittal T1 and/or STIR sequences of the whole spine, to prove or exclude the presence of spinal metastases. Sagittal T2 weighted sequences should also be performed to show the level and degree of compression of the cord or cauda equina by a soft tissue mass and to detect lesions within the cord itself. Supplementary axial imaging should be performed through any significant abnormality noted on the sagittal scan.Contact the MSCC coordinator to determine the most appropriate method of imaging for patients with suspected MSCC in whom MRI is contraindicated and where this should be carried out.Consider targeted CT scan with three-plane reconstruction to assess spinal stability and plan vertebroplasty, kyphoplasty or spinal surgery in patients with MSCC.Consider myelography if other imaging modalities are contraindicated or inadequate. Myelography should only be undertaken at a neuroscience or spinal surgical centre because of the technical expertise required and because patients with MSCC may deteriorate following myelography and require urgent decompression.Do not perform plain radiographs of the spine either to make or to exclude the diagnosis of spinal metastases or MSCC.If MRI is not available at the referring hospital, transfer patients with suspected MSCC to a unit with 24-hour capability for MRI and definitive treatment of MSCC.Out of hours MRI should only be performed in clinical circumstances where there is an emergency need and intention to proceed immediately to treatment, if appropriate.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.2Imaging and treatment plans for adults with suspected spinal metastases3Imaging and treatment plans for adults with suspected metastatic spinal cord compressionSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG75", "drug": {}}}, {"category": "treatment", "id": "t923", "name": "treating metastatic spinal cord compression", "draggable": "true", "value": {"name": "treating metastatic spinal cord compression", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:treating metastatic spinal cord compression", "drug": {}}}, {"category": "treatment", "id": "t922", "name": "treating painful spinal metastases and preventing metastatic spinal cord compression", "draggable": "true", "value": {"name": "treating painful spinal metastases and preventing metastatic spinal cord compression", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:treating painful spinal metastases and preventing metastatic spinal cord compression", "drug": {}}}, {"category": "drug", "id": "d201", "name": "daytime", "draggable": "true", "value": {"name": "daytime", "time": "None", "period": "None", "dosage": "None"}}]}